Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why Organovo Holdings Inc. Stock Roared Higher

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Organovo Holdings (NYSEMKT: ONVO  ) , a company focused on tissue engineering for clinical testing applications, soared as much as 12% after announcing the first public opinion of a key opinion leader regarding the use of its 3-D liver assay test.

So what: According to an 8-K filing with the Securities and Exchange Commission, Dr. Adrian Roth, Head of Mechanistic Safety for Roche Pharmaceutical Research and Early Development at the Roche Innovation Center Basel, presented results from his work with the 3-D liver assay test in collaboration with Organovo scientists. Per the release, Organovo's 3-D liver system "was able to distinguish a toxic drug known to cause drug induced liver injury (DILI) from a close chemical analogue that is known to be non-toxic. Further, the toxicity of the toxic compound was detected at physiologically relevant doses, an important observation not previously reported with the same compounds in other model liver systems."

In addition to these findings, Organovo also reaffirmed its product development forecast, with plans to launch its 3-D liver assay before the end of 2014. It did note, however, that it's granted access to its liver assay system to select clients with specific testing needs in the preclinical setting. These contracts would be expected to expand to a broader audience once the product is officially launched.

Now what: Obviously getting a positive review of its 3-D liver assay from a well-respected doctor is good news for Organovo, but the bigger deal in my view is the company again sticking to its launch timeline. Shareholders have a lot of high hopes for this Star Trek-like tissue engineering company, but they'll need to see some real world revenue generation before it can move to the next level. While I would have a hard time arguing that the data thus far isn't right on par with expectations, following a huge run higher over the past couple of years I'm inclined to stick to the sidelines and see how successful the initial launch of Organovo's first product turns out to be. Make no mistake, though, this is a stock I strongly encourage investors that are looking for the next cutting-edge health-care technology to keep their eyes on.

Organovo may be soaring today, but keeping up with this potential of this product over the long run could prove impossible! 
The best health care investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Read/Post Comments (0) | Recommend This Article (15)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3009819, ~/Articles/ArticleHandler.aspx, 8/30/2015 6:48:52 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Sean Williams

A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the healthcare sector and in investment planning topics. You'll usually find him writing about Obamacare, marijuana, developing drugs, diagnostics, and medical devices, Social Security, taxes, or any number of other macroeconomic issues.

Today's Market

updated 1 day ago Sponsored by:
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 1.21 0.06%
NASD 4,828.33 15.62 0.32%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/28/2015 4:00 PM
ONVO $2.54 Up +0.04 +1.60%